Nilotinib and paclitaxel for rare solid tumors
Part of Cancer clinical trials.
This study tests a combination of two drugs, nilotinib and paclitaxel, in people with certain rare cancers that have not responded to standard treatments. It aims to see if this combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have one of these rare cancers: adult granulosa cell ovarian cancer, clear cell ovarian cancer, anal cancer, or Ewing sarcoma.
- Your cancer must have progressed on standard treatment, or there must be no standard treatment for your cancer.
- You need to be in generally good health, with adequate liver, kidney, and bone marrow function.
- You must be willing to use effective birth control during the study and for 3 months after treatment ends.
- You cannot have significant nerve damage (neuropathy) or certain heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized approach for people with rare advanced or metastatic solid tumors. Doctors use special lab tests on your tumor tissue and blood to find the best treatment for you.
This study tests a combination of two medications, entinostat and an oral form of paclitaxel, for people with advanced breast cancer that is hormone receptor positive and HER2-negative. If you've already tried several treatments, this might be a new option to help slow the cancer's growth.
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
This trial tests paclitaxel given as tiny micelle particles for people whose cancer (pancreatic, bile duct, lung, stomach, esophagus, or breast) stopped responding to taxane chemotherapy or did not shrink. The goal is to see if this treatment can help when standard taxanes no longer work.
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.